10 research outputs found
M402, a Novel Heparan Sulfate Mimetic, Targets Multiple Pathways Implicated in Tumor Progression and Metastasis
Heparan sulfate proteoglycans (HSPGs) play a key role in shaping the tumor microenvironment by presenting growth factors, cytokines, and other soluble factors that are critical for host cell recruitment and activation, as well as promoting tumor progression, metastasis, and survival. M402 is a rationally engineered, non-cytotoxic heparan sulfate (HS) mimetic, designed to inhibit multiple factors implicated in tumor-host cell interactions, including VEGF, FGF2, SDF-1α, P-selectin, and heparanase. A single s.c. dose of M402 effectively inhibited seeding of B16F10 murine melanoma cells to the lung in an experimental metastasis model. Fluorescent-labeled M402 demonstrated selective accumulation in the primary tumor. Immunohistological analyses of the primary tumor revealed a decrease in microvessel density in M402 treated animals, suggesting anti-angiogenesis to be one of the mechanisms involved in-vivo. M402 treatment also normalized circulating levels of myeloid derived suppressor cells in tumor bearing mice. Chronic administration of M402, alone or in combination with cisplatin or docetaxel, inhibited spontaneous metastasis and prolonged survival in an orthotopic 4T1 murine mammary carcinoma model. These data demonstrate that modulating HSPG biology represents a novel approach to target multiple factors involved in tumor progression and metastasis
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI
Treatment of atherosclerotic disease often focuses
on reducing plasma LDL-cholesterol or increasing
plasma HDL-cholesterol. We examined in vitro the effects
on HDL receptor [scavenger receptor class B type I (SR-BI)]
activity of three classes of clinical and experimental plasma
HDL-cholesterol-elevating compounds: niacin, fibrates, and
HDL376. Fenofibrate (FF) and HDL376 were potent (IC50
? 1 mM), direct inhibitors of SR-BI-mediated lipid transport
in cells and in liposomes reconstituted with purified SR-BI.
FF, a prodrug, was a more potent inhibitor of SR-BI than an
activator of peroxisome proliferator-activated receptor a, a
target of its active fenofibric acid (FFA) derivative. Nevertheless,
FFA, four other fibrates (clofibrate, gemfibrozil,
ciprofibrate, and bezafibrate), and niacin had little, if any,
effect on SR-BI, suggesting that they do not directly target
SR-BI in vivo. However, similarities of HDL376 treatment
and SR-BI gene knockout on HDL metabolism in vivo
(increased HDL-cholesterol and HDL particle sizes) and
structure-activity relationship analysis suggest that SR-BI
may be a target of HDL376 in vivo. HDL376 and other
inhibitors may help elucidate SR-BI function in diverse
mammalian models and determine the therapeutic potential
of SR-BI-directed pharmaceuticals.ÂNieland, T. J. F.,
J. T. Shaw, F. A. Jaipuri, Z. Maliga, J. L. Duffner, A. N.
Koehler, and M. Krieger. Influence of HDL-cholesterolelevating
drugs on the in vitro activity of the HDL receptor
SR-BI
Recommended from our members
Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor
Background
The goal of this study is to use comprehensive molecular profiling to characterize clinical response to anti-TNF therapy in a real-world setting and identify reproducible markers differentiating good responders and non-responders in rheumatoid arthritis (RA).
Methods
Whole-blood mRNA, plasma proteins, and glycopeptides were measured in two cohorts of biologic-naĂŻve RA patients (n =â40 and n =â36) from the Corrona CERTAIN (Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory coNditions) registry at baseline and after 3âmonths of anti-TNF treatment. Response to treatment was categorized by EULAR criteria. A cell type-specific data analysis was conducted to evaluate the involvement of the most common immune cell sub-populations. Findings concordant between the two cohorts were further assessed for reproducibility using selected NCBI-GEO datasets and clinical laboratory measurements available in the CERTAIN database.
Results
A treatment-related signature suggesting a reduction in neutrophils, independent of the status of response, was indicated by a high level of correlation (Ïâ=â0.62; pâ<â0.01) between the two cohorts. A baseline, response signature of increased innate cell types in responders compared to increased adaptive cell types in non-responders was identified in both cohorts. This result was further assessed by applying the cell type-specific analysis to five other publicly available RA datasets. Evaluation of the neutrophil-to-lymphocyte ratio at baseline in the remaining patients (nâ=â1962) from the CERTAIN database confirmed the observation (odds ratio of good/moderate responseâ=â1.20 [95% CIâ=â1.03â1.41, pâ=â0.02]).
Conclusion
Differences in innate/adaptive immune cell type composition at baseline may be a major contributor to response to anti-TNF treatment within the first 3âmonths of therapy
Equivalent Gene Expression Profiles between Glatopaâą and CopaxoneÂź
Glatopaâą is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and CopaxoneÂź. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate--responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and sample-level (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa
A global benchmark study using affinity-based biosensors
International audienceTo explore the variability in biosensor studies, 150 participants from 20 countries were given the same protein samples and asked to determine kinetic rate constants for the interaction. We chose a protein system that was amenable to analysis using different biosensor platforms as well as by users of different expertise levels. The two proteins (a 50-kDa Fab and a 60-kDa glutathione S-transferase [GST] antigen) form a relatively high-affinity complex, so participants needed to optimize several experimental parameters, including ligand immobilization and regeneration conditions as well as analyte concentrations and injection/dissociation times. Although most participants collected binding responses that could be fit to yield kinetic parameters, the quality of a few data sets could have been improved by optimizing the assay design. Once these outliers were removed, the average reported affinity across the remaining panel of participants was 620 pM with a standard deviation of 980 pM. These results demonstrate that when this biosensor assay was designed and executed appropriately, the reported rate constants were consistent, and independent of which protein was immobilized and which biosensor was used. (C) 2008 Elsevier Inc. All rights reserved